Advanced search
Publication Cover
Current Opinion on Therapeutic Patents Volume 2, 1992 - Issue 4
Journal homepage
6
Views
7
CrossRef citations to date
0
Altmetric
Anti-Inflammatory, Anti-Allergic, Respiratory & GI Agents

Patent Update: Phospholipase A2 Inhibitors

Michael E Garst Allergan Phannaceuticals, 2525 Dupont Drive, Irvine, CA 92715
Pages 400-408 | Published online: 02 Mar 2011

References

  • Vadas P, Stefanski E, Pruzanski W Characterization of extracellular phospholipase A2 in rheumatoid synovial fluid. Life Sci. 1985 36 579.
  • Vadas P Elevated plasma phospholipase A2 levels: Correlation with the hemodynamic and pulmonary changes in Gram-negative septic shock. J. Lab. Clin. Med. 1984 104 873.
  • Nevalainen TJ The role of phospholipase A in acute pancreatitis. Scand J. Gastroent. 1980 15 641.
  • Forster S, Ilderton E, Norris JFB, Summerly R, Yardley HJ Characterization and activity of phospholipase A2 in normal human epidermis and in lesion-free epidermis of patients with psoriasis or eczema. Br. J. Derm. 1985 112 135.
  • Blackwell GJ, Carnuccio R, Di Rosa M, Flower RJ, Parente L, Persico P. Macrocortin: A polypeptide causing the anti-phospholipase effects of glucocorticoids. Nature 1980 287 147.
  • Hirata F, Lipomodulin: A possible mediator of the action of glucocorticoids, Advances in Prostaglandin, Thromboxane and Leukotriene Research Samuelsson B Raven Press NY 1983 11 73–78.
  • Flower RF Lipocortin and the mechanism of action of the glucocorticoids. Br. J. Pharmacol. 1988 94 987.
  • Davidson FF, Dennis EA, Powell M, Glenney JR Jr. Inhibition of phospholipase A2 by ‘Lipocortins’ and calpactins. J. Biol. Chem. 1987 262 1698.
  • Ahn NG, Teller DC, Bienkowski MJ, McMullen BA, Lipkin EW, Dehaeun C Sedimentation equilibrium analysis of five lipocortin-related phospholipase A2 inhibitors from human placenta. J. Biol. Chem. 1988 263 18657.
  • Hope WC, Patel BJ, Bolin DR (HDMNK VLDL) does not inhibit phospholipase A2 activities. Agents Actions 1991 34 77.
  • Benveniste J, Chignard M, Le Couedic JP, Bargaftig BB Biosynthesis of platelet-activation factor (PAF-Acether). II. Involvement of phospholipase A2 in the formation of PAF-acether and lyso-PAF-acether from rabbit platelets. Thrombosis Res. 1982 25 375.
  • Chilton FH, Ellis JM, Olson SC, Wykle RL 1–0-Alkyl-2-arachidonoyl-snglycero-3-phosphocholine: A common source of platelet-activating factor and arachidonate in human polymorphonuclear leukocytes. J. Biol. Chem. 1984 259 12014.
  • Mueller HW, O'Flaherty JT, Wykle RL Biosynthesis of platelet-activating factor in rabbit polymorphonuclear neutrophils. J. Biol. Chem. 1983 258 6213.
  • Sobel BE, Corr PB Biochemical mechanisms potentially responsible for lethal arrhythmias induced by ischemia: The lysolipid hypothesis. Adv. Cardiol. 1979 26 76.
  • Chien KR, Reeves JP, Buja LM, Bonte F, Parkey RW, Willerson JT Phospholipid alterations in canine ischemic myocardium. Circ. Res. 1981 48 711.
  • Van Kuijk FJGM, Sevanian A, Handelman GJ, Dratz EA A new role for phospholipase A2: Protection of membranes from lipid peroxidation damage. Trends Biochem. Sci. 1987 12 31.
  • Ripka WC, Sipio WJ, Galbraith WG Molecular modeling in the design of phospholipase A2 inhibitors. J. Cell. Biochem. 1989 40 279.
  • Magola RL, Galbraith W Design and synthesis of conformationally restricted phospholipids as phospholipase A2 inhibitors. J. Cell Biochem. 1989 40 371.
  • Noel JP, Deng T, Hamilton KJ, Tsai M-O Phospholipase engineering 3. Replacement of lysine-56 by neutral residues improves catalytic potency significantly, alters substrate specificity and clarifies the mechanism of interfacial recognition. J. Am. Chem. Soc. 1990 112 3704.
  • Yuan W, Quinn DM, Sigler PB, Gelb MH Kinetic and inhibition studies of phospholipase A2 with short-chain substrates and inhibitors. Biochemistry 1990 29 6082.
  • De Haas GH, Van Oort MG, Dijkaman R, Verger R Phospholipase A2 inhibitors: Monacyl, monoacylamino-glycero-phosphocholines. Biochem. Soc. Trans. 1989 17 274.
  • Campbell MM, Fox JL, Sainsbury M, Liu Y Synthesis of structural variants of phospholipids: Inhibition of phospholypase A2. Tetrahedron 1989 45 4551.
  • Connolly S, Robinson DH, Bennion C, Gensmantel N, Primrose WU, Slaich PK, Roberts GCK, Investigation into the binding of some substrate analogue inhibitors of phospholipase A2. 6th SCI-RSC Medicinal Symposium1991 Abstr #15.
  • Waszkowycz B, Hillier IH, Gensmantel N, Payling DW A theoretical study on hydrolysis by phospholipase A2: The catalytic role of the active site and substrate specificity. J. Chem. Soc. Perkin. Trans. 1990 2 1259.
  • Washburn WW, Dennis EA Suicide-inhibitory bifunctional linked substrates (SIBLINKS) as phospholipase A2 inhibitors. J. Biol. Chem. 1991 266 5042.
  • Scott DL, White SP, Otwinowski Z, Yuan W, Gelb MH, Sigler PB Interfacial catalysis: The mechanism of phospholipase A2. Science 1990 250 1541.
  • White SP, Scott DL, Otwinowski Z, Gelb MH, Sigler PB Crystal structure of cobra-venom phospholipase A2 in a complex with a transition-state analogue. Science 1990 250 1560.
  • Scott DL, Otwinowski Z, Gelb MH, Sigler PB Crystal structure of bee-venom phospholipase A2 in a complex with a transition-state analogue. Science 1990 250 1563.
  • Wery J-P, Schevitz RW, Clawson DK, Bobbitt JL, Dow ER, Gamboa G, Goodson T Jr, Hermann RB, Kramer RM, McClure DB, Mihelich ED, Putnam JE, Sharp DH, Stark DH, Teater C, Warrick MW, Jones ND Structure of recombinant human rheumatoid arthritic synovial fluid phospholipase A2 at 2.2A resolution. Nature 1991 352 79.
  • Scott DL, White SP, Browining JL, Rosa JJ, Gelb MH, Sigler PB Structures of free and inhibited human secretory phospholipase A2 from inflammatory exudate. Science 1991 254 1007.
  • Kramer RM, Hession C, Johansen B, Hayes G, McGray P, Chow EP, Tizard R, Pepinsky RB Structure and properties of a human non-pancreatic phospholipase A2. J. Biol. Chem. 1989 264 5768.
  • Seilhamer JJ, Pruzanski W, Vadas P, Plant S, Miller JA, Kloss J, Johnson LK Cloning and recombinant expression of phospholipase A2 present in rheumatoid arthritic synovial fluid. J. Biol. Chem. 1989 264 5335.
  • Ochuchi K, Watanabe M, Numajiri N, Tsurufuki S Phospholipase A2 activity in carrageenin-induced inflammatory tissue of rats. Biochem. Pharm. 1982 31 2993.
  • Fischer SM, Mills GD, Slaga TJ Inhibition of mouse skin tumor promotion by several inhibitors of arachidonic acid metabolism. Carcinogenesis 1982 3 1243.
  • Nakadate T, Yamamoto S, Ishii M, Kato R Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced epidermal decarboxylase activity by phospholipase A2 inhibitors and lipoxygenase inhibitor. Cancer Res. 1982 42 2841.
  • Glaser KB, Lock YW, Chang JY PAF and LTB4 biosynthesis in the human neutrophil: Effects of putative inhibitors of phospholipase A2 and specific inhibitors of 5-lipoxygenase. Agents Actions 1991 34 89.
  • Stanley PL, Steiner S, Havens M, Tamposhch KM Mouse skin inflammation induced by multiple topical applications of 12-O-tetradecanoylphorbol-13-acetate. Skin Pharmacol. 1991 4 262.
  • Crowl RM, Stoller TJ, Conroy RR, Stoner CR Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. J. Biol. Chem. 1991 266 2647.
  • Mobilio D, Marshal LA Recent advances in the design and evaluation of inhibitors of phospholipase A2. Ann. Rep. Med. Chem. 1989 24 157.
  • Wilkerson WE Anti-inflammatory phospholipase A2 inhibitors. Drugs Future 1990 15 139.
  • Wilkerson W, DeLucca I, Galbraith W, Gans K, Harris R, Jaffee B, Kerr J Antiinflammatory phospholipase-A2 inhibitors. I. Eur. J. Med. Chem. 1991 26 667.
  • Carlson RP, O'Neill-Davis L, Chang J, Lewis AJ Modulation of mouse ear edema by cyclooxygenase and lipoxygenase inhibitors and other pharmacologic agents. Agents Actions 1985 17 197.
  • Jacobson PB, Marshall LA, Sung A, Jacobs RS Inactivation of human synovial fluid phospholipase A2 by the marine natural product. Manoalide. Biochem. Pharm. 1990 39 1557.
  • De Carvalho MS, Jacobs RS Two-step inactivation of bee venom phospholipase A2 by scalaradial. Biochem. Pharmacol. 1991 42 1621.
  • Reynolds LJ, Mihelich ED, Denniss EA Inhibition of venom phospholipase A2 by manoalide and manoalogue. J. Biol. Chem. 1991 266 16512.
  • Nettleton D, Havens M, Marathe S, Zusi FC, Tramposch KM Phospholipase A2 inhibition by dihydrofuranones. 5th Inflammation Res. Assoc. 1990 Abstr. #92.
  • De Vries G, Lee GCM, Amdahl L, Wenzel M, Harcourt D, Holmes J, Syage E, Garst ME, Wheeler LA AGN 190093. Drugs Future 1990 15 460.
  • Lee G, De Vries G, Harcourt D, Holmes J, Amdahl L, Syage E, Wenzel M, Wheeler LA, Garst ME AGN 190383. Drugs Future 1990 15 561.
  • Devries G, AGN 190383. A novel phospholipase inhibitor with topical antiinflammatory activity. Agents Actions 1991 34 70.
  • Caufield CE, Marshall L, Sung A, Lock T, Glaser KB, Carlson RP, Musser JH Inhibition of phospholipase A2 by ellagic acid and derivatives. 5th Inflammation Res. Assoc. 1990 Abstr #94.
  • Kreft A, Nelson J, Musser J, Shah' U, Kubrak D, Banker A, Failli A, Steffan R, Schieher G, Sturm R, Hollooway D, Carlson R, Berkenkopf J, Howell R, Woeppel S, Gray W, Grimes D, Weichman B, Chang J, Bauer J, Sung MLK, Lock Y, Marshall L, Glaser K, Structure activity relationships leading to WAY121520. A trisaryl indomethacin-based PLA2 inhibitor. 203 ACS Meeting Abstract1992 Medchm 144.
  • Oniuma H, Takamura T, Hasegawa T, Nomoto K-I, Naitoh T, Daiku Y, Hamano S, Kakisawa H, Minami N Synthesis and biological evaluation of substituted benzenesulfonamides as novel potent membrane-bound phospholipase A2 inhibitors. J. Med. Chem. 1991 34 2260.
  • Yamakawa T, Kagechika H, Kawachi E, Hashimoto Y, Shudo K Retinobenzoic acids. 5. Retinoid activities of compounds having a trimethylsilyl or trimethylgermyl group(s) in human promyelocytic leukemia cells HL-60. J. Med. Chem. 1990 33 1430.
  • Hope WC, Patel BJ, Fiedler-Nagy C, Wittreich BH Retinoids inhibit phospholipase A2 in human synovial fluid and arachidonic acid release from rat peritoneal macrophages. Inflammation 1990 14 543.
  • Fawzy AA, Vishwanath BS, Franson RC Inhibition of human non-pancreatic phospholipase A2 by retinoids and flavnoids. Mechanism of Action. Agents Actions 1988 25 394.
  • Finnen MJ, Lovell CR Inhibition of human epidermal phospholipase A2 by polyunsaturated fatty acids. Brit. J. Derm. 1990 123 56.
  • Aoki M, Itezono Y, Shirai H, Nakayama N, Sakai A, Tanaka Y, Yamaguchi A, Shimma N, Yokose K, Seto H Structure of a novel phospholipase C inhibitor, vinaxanthone (RO9–1450). Produced by penicillium vinaceum. Tetrahedron Lett. 1991 32 4737.

References to Patent Literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.